CLCFF Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of 14.06% compared to Christina Lake Cannabis Corp.'s net margin of 42.95%. Christina Lake Cannabis Corp.'s return on equity of -4.97% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Christina Lake Cannabis Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 3.01%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than Christina Lake Cannabis Corp., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than Christina Lake Cannabis Corp..

Christina Lake Cannabis Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Christina Lake Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Christina Lake Cannabis Corp. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Christina Lake Cannabis Corp. quarterly revenues are $1.7M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Christina Lake Cannabis Corp.'s net income of $2.5M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Christina Lake Cannabis Corp.'s price-to-earnings ratio is 3.15x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Christina Lake Cannabis Corp. is 0.53x versus 8.59x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instadose Pharma Corp. has a net margin of 14.06% compared to Christina Lake Cannabis Corp.'s net margin of --. Christina Lake Cannabis Corp.'s return on equity of -4.97% beat Instadose Pharma Corp.'s return on equity of --.

Christina Lake Cannabis Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Instadose Pharma Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Christina Lake Cannabis Corp. has higher upside potential than Instadose Pharma Corp., analysts believe Christina Lake Cannabis Corp. is more attractive than Instadose Pharma Corp..

Christina Lake Cannabis Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Instadose Pharma Corp. has a beta of -714.392, suggesting its less volatile than the S&P 500 by 71539.203%.

Christina Lake Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instadose Pharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Christina Lake Cannabis Corp. pays -- of its earnings as a dividend. Instadose Pharma Corp. pays out -- of its earnings as a dividend.

Christina Lake Cannabis Corp. quarterly revenues are $1.7M, which are larger than Instadose Pharma Corp. quarterly revenues of --. Christina Lake Cannabis Corp.'s net income of $2.5M is higher than Instadose Pharma Corp.'s net income of --. Notably, Christina Lake Cannabis Corp.'s price-to-earnings ratio is 3.15x while Instadose Pharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Christina Lake Cannabis Corp. is 0.53x versus -- for Instadose Pharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 14.06% compared to Christina Lake Cannabis Corp.'s net margin of --. Christina Lake Cannabis Corp.'s return on equity of -4.97% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Christina Lake Cannabis Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 449.6%. Given that Oncolytics Biotech, Inc. has higher upside potential than Christina Lake Cannabis Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than Christina Lake Cannabis Corp..

Christina Lake Cannabis Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Christina Lake Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Christina Lake Cannabis Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Christina Lake Cannabis Corp. quarterly revenues are $1.7M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Christina Lake Cannabis Corp.'s net income of $2.5M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Christina Lake Cannabis Corp.'s price-to-earnings ratio is 3.15x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Christina Lake Cannabis Corp. is 0.53x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of 14.06% compared to Christina Lake Cannabis Corp.'s net margin of -163.68%. Christina Lake Cannabis Corp.'s return on equity of -4.97% beat Venus Concept, Inc.'s return on equity of -1236.95%.

Christina Lake Cannabis Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 5972.92%. Given that Venus Concept, Inc. has higher upside potential than Christina Lake Cannabis Corp., analysts believe Venus Concept, Inc. is more attractive than Christina Lake Cannabis Corp..

Christina Lake Cannabis Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.

Christina Lake Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Christina Lake Cannabis Corp. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

Christina Lake Cannabis Corp. quarterly revenues are $1.7M, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. Christina Lake Cannabis Corp.'s net income of $2.5M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, Christina Lake Cannabis Corp.'s price-to-earnings ratio is 3.15x while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Christina Lake Cannabis Corp. is 0.53x versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.